STOCK TITAN
  1. Home
  2. News
  3. CNTA

Centessa Pharmaceuticals plc - CNTA STOCK NEWS

Welcome to our dedicated news page for Centessa Pharmaceuticals plc (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Centessa Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Centessa Pharmaceuticals plc's position in the market.

News
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Rhea-AI Summary
Centessa Pharmaceuticals plc (CNTA) reports recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023. The company is focused on the registrational studies of SerpinPC for hemophilia B, advancing its orexin agonist program, and evaluating its LockBody technology platform. Recent data shows promising results for SerpinPC, with a 96% reduction in bleeding rates, and no thrombosis observed. The company plans to share clinical proof-of-concept data for ORX750 in 2024. Financially, Centessa has $256.5 million in cash, research & development expenses of $29.7 million, general & administrative expenses of $12.3 million, and a net loss of $36.8 million for the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
earnings
-
News
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
Rhea-AI Summary
Centessa Pharmaceuticals plc (CNTA) to participate in TD Cowen's 44th Annual Health Care Conference in Boston, MA. A fireside chat scheduled for March 5th. Live audio webcast and archived recording available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
conferences
-
News
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announces the presentation of additional 52-week data from the ongoing Phase 2a study of SerpinPC for hemophilia treatment at EAHAD Congress. SerpinPC shows promise as a novel inhibitor of activated protein C, with positive results reinforcing its potential as a convenient subcutaneous treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.13%
Tags
conferences clinical trial
News
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced its participation in upcoming investor conferences, including Guggenheim’s 6th Annual Biotechnology Conference and Leerink Partners Global Biopharma Conference 2024. The live webcasts and archived recordings will be available on the company's investor relations section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
conferences
-
News
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Saurabh Saha MD PhD, CEO, to present on January 10, 2024, at 4:30 PM PST. The event will be available for live audio webcast and archived recording on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
conferences
-
News
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) presented additional data from the third year of the Phase 2a study of SerpinPC for the treatment of hemophilia at the American Society of Hematology (ASH) Annual Meeting. The data showed a 96% reduction in the median all-bleed annualized bleeding rate (ABR) from the prospective baseline, reinforcing the favorable safety and tolerability profile of SerpinPC. No thromboembolic events or treatment-related sustained elevations of D-dimer were observed during the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA): Ongoing studies for hemophilia B treatment, new data at ASH Annual Meeting, preclinical data on narcolepsy treatment presented at World Sleep Congress, financial results and business highlights for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
earnings
-
News
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
Rhea-AI Summary
Centessa Pharmaceuticals announced that new data from the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia will be presented at the 65th ASH Annual Meeting. SerpinPC is an investigational inhibitor of activated protein C in registrational studies for hemophilia B. The Phase 2a study is investigating the safety, tolerability, pharmacokinetics, and efficacy of SerpinPC in male participants with severe hemophilia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
News
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
Rhea-AI Summary
Centessa Pharmaceuticals has announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors. The study is a Phase 2b, global, open-label study to investigate the efficacy and safety of subcutaneous dosing of SerpinPC. The primary efficacy endpoint is the rate of treated bleeds compared to the first 24 weeks of treatment with SerpinPC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
News
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that its management team will participate in two upcoming investor conferences: Jefferies London Healthcare Conference on November 15, 2023, in London, and Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023, in Miami, FL. Access to live webcasts and archived recordings will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
conferences
Stock CNTA logo
Centessa Pharmaceuticals plc

Nasdaq:CNTA

CNTA Rankings

#2357 Ranked by Market Cap
#346 Ranked by Stock Gains
N/A Ranked by Dividends

CNTA Stock Data

1.14B
43.89M
2.33%
84.02%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Altrincham

About CNTA

centessa pharmaceuticals plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. the company applies an asset-centric r&d model at scale to advance a portfolio of highly validated programs led by industry leading teams. each program is developed by a centessa subsidiary and supported by a centralized infrastructure and the centessa management team. the company is headquartered in cambridge, mass.